Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.82 HKD | +2.51% | +14.06% | -20.08% |
Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
11,988 GBX | -0.32% | +9.52% | 231B | ||
18.82 HKD | +2.51% | +14.06% | 1.1B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.08% | 1.1B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- 6185 Stock
- News CanSino Biologics Inc.
- INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca